Merck grabs FDA green light for less-frequent Keytruda dosing regimen

Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!!   That didn’t take long. Just days after resubmitting its application to the FDA, Merck has nabbed an approval for a new dosing regimen of its immuno-oncology blockbuster, Keytruda. The FDA green-lighted the label update Tuesday, clearing the product for use in 400mg … Συνεχίστε να διαβάζετε Merck grabs FDA green light for less-frequent Keytruda dosing regimen.

5 questions ESMO cancer drug data might answer

5 questions ESMO cancer drug data might answer

Roche’s Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals

Roche's Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals

Following Rova-T Failure, AbbVie Enters Immuno-Oncology Deal with Idera

Following Rova-T Failure, AbbVie Enters Immuno-Oncology Deal with Idera